StemRIM (4599) · RiskDropped
More cautious funding conditions for biotech companies and the need to prioritize and focus the development pipeline
First written in FY2025-H1. 1 of 2 entries say "Dropped", first in FY2025. Latest entry: FY2025.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Risk of difficulty raising additional funds on favorable termsA theme 23 companies write about · 25 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2026: 8 of 18 companies on the "Worse" side.
0 other companies' latest entry also says "Dropped".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 23 companies compared. The sentences above are computed from all 23.Full recordFilings, disclosures and news, newest first
- FY2025DroppedAnnual reportThe explicit description in the previous filing of more cautious financing conditions for biotech companies due to the global financial environment, and the prioritisation and concentration of pipelines, cannot be found in the current annual securities report.
- FY2025-H1First statedAnnual report
「Meanwhile, changes in the global financial environment have kept biotech companies' financing conditions cautious, creating a situation in which greater prioritisation and concentration of development pipelines is required.」
The more cautious financing conditions for biotech companies resulting from changes in the global financial environment, and the resulting need to prioritise and concentrate development pipelines, are newly described as risks and aspects of the business environment.